


I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on December 8, 2008

PATENT
Attorney Docket No.: 015270-008920US

TOWNSEND and TOWNSEND and CREW LLP

By: 
Tina Trier

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: 10/699,517

Filed: October 31, 2003

For: PREVENTION AND TREATMENT
OF SYNUCLEINOPATHIC DISEASE

Customer No.: 20350

Confirmation No.: 8113

Examiner: Daniel E. Kolker

Art Unit: 1649

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR §1.98(a)(2), copies of the non US patent cite nos. 222-238 are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant cites the following applications which are directed to related subject matter and are commonly owned or under an assignment obligation to be commonly owned by Elan Pharmaceuticals, Inc. and The Regents of the University of California:

60/984,721 filed 11/01/2007;

11/894,772 filed 08/20/2007;
11/894,744 filed 08/20/2007;
11/894,605 filed 08/20/2007;
11/842,054 filed 08/20/2007;
11/841,996 filed 08/20/2007;
11/697,646 filed 04/06/2007;
11/710,248 filed 02/23/2007;
11/660,015 filed 02/09/2007 (U.S. Nat'l Stage entry of PCT/US05/28166);
11/185,907 filed 07/19/2005 published as 2006/0058233 on 03/16/2007;
10/915,214 filed 08/09/2004 published as 2005/0037013 on 02/17/2005;
10/698,099 filed 10/31/2003 published as 2004/0146521 on 07/29/2004;
10/699,517 filed 10/31/2003 published as 2004/0136993 on 07/15/2004; and
60/423,012 filed 11/01/2002.

Applicant also cites the following applications directed to related subject matter but subject to different assignment:

11/194,115 filed 07/29/2005 published as 2006/0259986 on 11/16/2006;
10/984,192 filed 11/08/2004 published as 2005/0196818 on 09/08/2005;
10/969,335 filed 10/19/2004 published as 2005/0198694 on 09/08/2005; Notice of Allowance mailed 07/20/2007;
10/850,570 filed 05/19/2004 abandoned 09/26/2004;
60/518,140 filed 11/08/2003; and
60/471,929 filed 05/19/2003.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed on or before payment of the issue fee.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:t4t
61720253 v1